[CAS NO. 68-96-2] 17α-Hydroxyprogesterone
PRODUCTS SPECIFICATIONS [68-96-2]
DESCRIPTION [68-96-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 330.46 |
| Molecular Formula | C21H30O3 |
| SMILES | CC([C@@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O)=O |
1 Publications Citing Use of MCE
Summary
17α-Hydroxyprogesterone (17-Hydroxyprogesterone) is an endogenous progestogen as well as chemical intermediate in the biosynthesis of other steroid hormones, including the corticosteroids and the androgens and the estrogens.
IC50 & Target
|
Human Endogenous Metabolite |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03433040 | University of South Florida|Washington University School of Medicine |
Premature Birth|Absorption; Chemicals
|
August 23, 2017 | Phase 3 |
| NCT01050647 | Stanford University |
Pregnancy Complications
|
February 2010 | Phase 1|Phase 2 |
| NCT04807543 | Ain Shams University |
Preterm Premature Rupture of Membrane
|
January 10, 2018 | Phase 2 |
| NCT04183452 | Steve N. Caritis, MD|AMAG Pharmaceuticals, Inc.|University of Pittsburgh |
Preterm Birth
|
June 16, 2020 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 50 mg/mL ( 151.30 mM ; Need ultrasonic)
H 2 O : < 0.1 mg/mL (insoluble)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.0261 mL | 15.1304 mL | 30.2609 mL |
| 5 mM | 0.6052 mL | 3.0261 mL | 6.0522 mL |
| 10 mM | 0.3026 mL | 1.5130 mL | 3.0261 mL |
Synonyms